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Sex Differences in Outcome with Bevacizumab Therapy
Analysis of Patients with Advanced-Stage Non-small Cell Lung
Cancer Treated with or without Bevacizumab in Combination with
Paclitaxel and Carboplatin in the Eastern Cooperative Oncology
Group Trial 4599
Julie R. Brahmer, MD,* Suzanne E. Dahlberg, PhD,† Robert J. Gray, PhD,† Joan H. Schiller, MD,‡
Michael C. Perry, MD,§ Alan Sandler, MD, and David H. Johnson, MD‡
Introduction: E4599 compared carboplatin and paclitaxel with
(PCB) or without (PC) bevacizumab in patients with advanced-stage
non-small cell lung cancer. Bevacizumab improved overall survival.
However, an unplanned subset analysis did not show a survival
benefit for females treated with bevacizumab.
Methods: Known prognostic factors and toxicities were compared
by sex. Proportional hazards models of survival with multiple factor
combinations were used to adjust for treatment effect.
Results: The analysis includes 850 patients. The median survival
was 8.7 months (PC) versus 11.7 months (PCB) for males (p 
0.001) and 13.1 months (PC) versus 13.3 months (PCB) for females
(p  0.87). Progression-free survival and response rate on the PCB
arm were 6.3 months and 29% for males and 6.2 months and 41%
for females (p  0.05). Progression-free survival and response rate
on the PC arm were 4.3 months and 16% for males and 5.3 months
and 14% for females (p  0.05). No significant demographic
differences were seen between the two arms for males, whereas
fewer females on the PCB arm had liver metastasis (PCB 11.7%
versus PC 23.2%, p  0.003). Adverse events with a sex difference
on the PCB arm included severe hypertension (males: 4.2%, fe-
males: 9.9%, p  0.02), constipation (males: 1.4%, females: 4.7%,
p  0.05), and abdominal pain (males: 0.9%, females: 5.2%, p 
0.01). In the proportional hazards model adjusting for the other
factors, the test for a sex by treatment interaction was not significant
(p  0.09).
Conclusions: Multiple factors may contribute to the apparent sex-
specific differences in efficacy of bevacizumab noted in this study.
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Lung cancer is the leading cause of cancer-related deaths inthe United States in both men and women,1 killing more
women than breast, ovarian, and colon cancer combined.
Poor outcome is attributable to the fact that at least 40% of
patients present with advanced disease, which is incurable
with current treatment regimens. Before 2006, doublet chemo-
therapy (platinum or nonplatinum based) served as the standard
of care,2,3 affording a median survival of 8 to 10 months. With
the recognition of the importance of angiogenesis in cancer
growth and metastasis, various therapies have been developed to
block this pathway, including tyrosine kinase inhibitors of vas-
cular endothelial growth factor receptors and antibodies against
vascular endothelial growth factor.4–6
Bevacizumab, a monoclonal antibody targeting the vas-
cular endothelial growth factor, was approved by the Food
and Drug Administration for use in combination with pacli-
taxel and carboplatin for patients with advanced-stage,
nonsquamous non-small cell lung cancer (NSCLC).6,7 The
approval followed the positive results from the large ran-
domized Eastern Cooperative Oncology Group (ECOG)
trial 4599.8 ECOG 4599 compared chemotherapy alone
(paclitaxel and carboplatin [PC]) with the same regimen
plus bevacizumab (PCB) in patients with nonsquamous,
advanced-stage NSCLC. The PCB combination resulted in
a 2-month improvement in median overall survival (OS)
(PC 10.3 months versus PCB 12.3 months).8 However,
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patients on the PCB arm had higher rates of toxicities
including neutropenia, hemorrhage, hypertension, and pro-
teinuria. A higher incidence of treatment-related deaths
was also observed. Most of these toxicities are known side
effects of bevacizumab.
Several studies have demonstrated that females survive
longer than males with NSCLC, regardless of stage.9–13
Females also experience increased toxicity when treated with
chemotherapy compared with males.14 Wakelee et al.14 stud-
ied ECOG 1594, which randomized patients with advanced-
stage NSCLC to four different platinum-based chemotherapy
regimens. Females had a longer median survival (9.2 months
for females and 7.3 months for males [p  0.004]). Survival
was also better for females at 1, 2, and 3 years (38%, 14%,
and 7%, respectively, for females versus 31%, 11%, and 5%,
respectively, for males). The survival difference remained
statistically significant after adjusting for performance status
(PS), weight loss 10%, presence of brain metastases, and
stage (IIIB versus IV). This difference in survival remained in
both sex cohorts across all the chemotherapy regimens stud-
ied. In terms of toxicity, females tended to have more nausea,
vomiting, alopecia, neurosensory deficits, and neuropsychi-
atric deficits. Reasons for this remain unclear.
In an unplanned, exploratory, retrospective, subset
analysis of ECOG 4599, sex differences in outcome were also
seen.8 Although both sexes had an improved response rate
(RR) and progression-free survival (PFS) on PCB compared
with PC, females on the PCB arm did not have a longer
survival than females treated with PC alone. However, fe-
males lived longer than males on both arms by at least 2
months. Because of these inconsistent results and exceptional
median OS in females, we conducted a subset analysis of
ECOG 4599 to evaluate the potential causes of the apparent
lack of differences in survival with bevacizumab in females
and the excellent OS of the females in this trial.
PATIENTS AND METHODS
As a randomized phase II/III trial, ECOG 4599 evalu-
ated whether the addition of bevacizumab to standard che-
motherapy (paclitaxel and carboplatin) improved OS in pa-
tients with untreated advanced NSCLC. This trial included
patients with previously untreated stage IIIB (with a pleural
effusion) and stage IV disease; ECOG PS of 0 or 1; and
adequate bone marrow, hepatic, and renal function. This trial
excluded patients with squamous cell histology, with signif-
icant hemoptysis, with uncontrolled hypertension, on thera-
peutic anticoagulation, with brain metastasis, and with a
recent history of bleeding or thrombosis. Stratification factors
were measurable versus nonmeasurable disease, prior radia-
tion versus no prior radiation, prior weight loss 5% versus
5%, and stage IIIB with pleural effusion versus stage IV or
recurrent disease. Patients were treated with paclitaxel (200
mg/m2 intravenously [IV] on day 1) and carboplatin (area
under the curve of 6 mg/ml  min IV on day 1) and
randomized to treatment with or without bevacizumab (15
mg/kg IV on day 1). Patients were treated every 21 days (one
cycle), and tumor assessments were performed every two
cycles (every 6 weeks). Patients with stable or responding
disease after six cycles on the PCB arm then received bev-
acizumab as a single agent until progression or unacceptable
toxicity. Trial design did not allow for patient cross-over to
the bevacizumab arm. The study used the standard Response
Evaluation Criteria in Solid Tumors (RECIST) to determine
response and the National Cancer Institute Common Termi-
nology Criteria version 2.0 to grade toxicities. The study was
carried out in accordance with the Declaration of Helsinki,
current Food and Drug Administration Good Clinical Prac-
tices, and local institutional ethical and legal requirements.
The goal of the current analysis was to evaluate potential
reasons why the addition of bevacizumab to PC among females
did not appear to result in an improvement in OS compared with
PC and why females in general survived much longer than
expected. Comparisons of toxicity, prognostic factors, and effi-
cacy between males and females were performed.
Statistical Methods
Differences in baseline patient demographics and dis-
ease characteristics were compared using Fisher’s exact test,
as were RRs. OS was defined as the time from randomization
to death from any cause. PFS was defined as the time from
randomization to disease progression or death without pro-
gression; patients who died without documented progression
were censored at the date of their last disease assessment. The
Kaplan-Meier method was used to estimate the time-to-event
distributions and Cox’s proportional hazards models, strati-
fied on disease measurability (yes versus no), disease stage
(IIIB versus IV/recurrent), prior radiation (yes versus no), and
prior weight loss (5% versus 5%), were used to estimate
hazard ratios (HRs) and test for significance for OS. PFS and
duration of response distributions were compared using log-
rank tests. All p values are two sided, and no adjustments
have been made for multiple comparisons.
RESULTS
Patient Demographics
Of the 878 participants enrolled in the study, 850
eligible subjects are included in this analysis. Table 1 de-
scribes baseline patient demographics and disease character-
istics. Females accounted for 46% (n  387) of the subjects
in this trial. Fewer females on PC compared with PCB had
liver involvement (11.7% versus 23.2%, respectively, p 
0.003), compared with males on either the PC arm or PCB
arm (20.6% and 20.0%, respectively). A slightly higher
proportion of females on the PCB arm had 5% weight loss
before therapy compared with the females treated on the PC
arm (32.4% versus 24.4%, p  0.09). Fewer females on the
PC arm had more than two metastatic sites involved com-
pared with females on the PCB arm (45% versus 52.2%). The
characteristics of the male subjects were balanced on each
arm of therapy.
Efficacy
RR was assessed on 773 subjects with measurable
disease (Table 2). In the bevacizumab treatment group, RRs
were 34.9% compared with 15.1% in the chemotherapy-alone
arm (p  0.001). Both males and females experienced a
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higher RR when treated with PCB (28.8% versus 15.7%,
respectively, for men [p  0.001] and 41.1% versus 14.2%,
respectively, for women [p  0.001]). Stable disease rate at
8 weeks was similar between males on each arm (PC 41.7%
versus PCB 41.4%), whereas females had a slightly higher
stable disease rate on PC (47.5%) versus PCB (32.1%)
therapy. The duration of response was longer when treated
with PCB versus PC for the overall group. For men, the
duration of response was 6.8 months with PCB and 5.0
months with PC (p  0.05). For females, the duration of
response was 5.9 months with PCB and 4.9 months with PC
(p  0.06).
The addition of bevacizumab prolonged PFS for both
males and females. Males had a median PFS of 4.3 months
with PC versus 6.3 months with PCB with a HR of 0.64
(95% confidence interval [CI], 0.53–0.78, p  0.0001).
Females had a median PFS of 5.3 months with PC treat-
ment versus 6.2 months with PCB with a HR of 0.71 (95%
CI, 0.57–0.88, p  0.002).
Although OS was prolonged for the entire group when
treated with PCB (12.3 months for PCB versus 10.3 months
for PC), this effect seemed limited to males8 who had a
median OS of 8.7 months when treated with PC alone and
11.7 months when treated with PCB (HR  0.70, 95% CI,
0.57–0.87, p 0.001). Outcomes for females were similar on
both arms. The median OS for females treated with PC alone
was 13.1 months and 13.3 months when treated with PCB
(HR  0.98, 95% CI, 0.77–1.25, p  0.87).
The analysis explored potential imbalances in mainte-
nance bevacizumab therapy on the PCB arm as well as treatment
imbalances between females and males. The percent of males
and females receiving more than six cycles of maintenance
bevacizumab therapy was similar, 18.9% versus 22.4%, respec-
tively. Similarly, the percentage of males and females receiving
any maintenance bevacizumab doses was 52.9% versus 52.7%,
respectively. In addition, males and females on each arm re-
ceived the same median number of chemotherapy cycles. On the
PC arm, the median chemotherapy cycles delivered were four
for males and five for females. On the PCB arm, the median
number of cycles of therapy was 7.5 for males and 7 for females.
No differences were observed in the distribution of cycles
between males and females on each arm.
TABLE 2. Efficacy
PC PCB
Male
(n  230)
Female
(n  162)
Male
(n  191)
Female
(n  190)
RR (%) 15.7 14.2 28.8 41.1
PFS (mo) 4.3 5.3 6.3 6.2
OS (mo) 8.7 13.1 11.7 13.3
RR, response rate; PFS, Progression-free survival; OS, overall survival.
TABLE 3. Type of First Treatment Given at Progression
Type
PC (n  433) PCB (n  417)
Male Female Male Female
Nonchemotherapy 51 (12%) 26 (6%) 29 (7%) 31 (7%)
Chemotherapy 116 (27%) 89 (20%) 100 (24%) 85 (20%)
Not specified 0 0 1 (1%) 0
Nothing reported 86 (20%) 65 (15%) 80 (19%) 91 (22%)
TABLE 4. Specified Types of Treatment Given at Progression
(Categories Are Not Mutually Exclusive)
Type
PC PCB
Male
(n  167)a
Female
(n  115)a
Male
(n  129)a
Female
(n  116)a
Taxane 33 23 35 29
Gemcitabine 41 21 26 14
Other chemotherapy 39 43 37 39
Pemetrexed 4 9 6 7
EGFR 45 32 23 34
a The numbers do not add up because categories are not mutually
exclusive.
TABLE 1. Patient Demographics
Group
PC (n  433) PCB (n  417)
Male (n  253) Female (n  180) Male (n  210) Female (n  207)
Age 65 (yr) 117 (46.2%) 72 (40.0%) 96 (45.7%) 81 (39.1%)
ECOG PS1a 152 (60.6%) 108 (60.3%) 125 (60.1%) 122 (59.2%)
Prior radiation 24 (9.5%) 13 (7.2%) 18 (8.6%) 15 (7.2%)
Prior weight loss 5% 77 (30.4%) 44 (24.4%) 50 (23.8%) 67 (32.4%)
Stage IV nonrecurrent 200 (79.4%) 137 (76.1%) 160 (76.2%) 150 (72.5%)
Histology: adeno or NOS 223 (88.8%) 157 (87.2%) 179 (85.2%) 187 (90.3%)
Large cell 17 (6.8%) 12 (6.7%) 12 (5.7%) 5 (2.4%)
Bronchiolo-alveolar carcinoma 6 (2.4%) 5 (2.8%) 7 (3.3%) 5 (2.4%)
Other histology 5 (2.0%) 6 (3.3%) 12 (5.7%) 10 (4.8%)
2 metastatic sites involved 148 (58.5%) 81 (45.0%) 108 (51.4%) 108 (52.2%)
Liver involved 52 (20.6%) 21 (11.7%) 42 (20.0%) 48 (23.2%)
a Six cases were excluded from PS rates due to unknown PS.
ECOG PS, Eastern Cooperative Oncology Group performance status; BAC, bronchioloalveolar carcinoma; NOS, not otherwise specified.
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Tables 3 and 4 display potential imbalances in therapy
given at the time of progression. Unfortunately, for at least
35% of the patients on each treatment arm, subsequent
treatment was not reported, limiting our analysis. Of those
patients for whom the study documented second-line treat-
ment, approximately 20 to 27% of patients were administered
some type of chemotherapy in the second-line setting. A
lower number of females received second-line therapy on
both treatment arms compared with males. On PC alone, 20%
of the females received second-line therapy compared with
27% of the males. On the PCB arm, 20% of the females
received second-line chemotherapy compared with 24% of
the males. No differences were noted between the type of
second-line therapy given and treatment arms or sex in Table
4. Epidermal growth factor receptor tyrosine kinase inhibitors
were prescribed in similar proportions in males and females
across the treatment arms (9–16%). Because of the numbers
of subjects without this information recorded, a statistical
analysis could not be performed.
Toxicity
Toxicities were assessed in 867 subjects at the time of
this analysis. Grade 3 and higher toxicities were compared
between sexes and treatment groups. In ECOG 4599, case
report forms only recorded grade 3 and greater toxicities
(grade 4 or higher for hematologic events). Toxicities to
therapy are noted in Table 5.
Subjects treated on the bevacizumab arm experienced
more antiangiogenesis therapy toxicities such as hypertension
and hemoptysis. Comparing males and females on each arm,
females treated with bevacizumab had a higher rate of grade
3 hypertension compared with males (9.9% versus 4.2%,
respectively, p  0.02). Hemoptysis, other bleeding events,
and proteinuria occurred similarly between males and fe-
males on the bevacizumab arm.
Patients treated with bevacizumab and chemotherapy
experienced more hematologic toxicities.8 Neutropenia, ane-
mia, and thrombocytopenia occurred at similar rates in males
and females treated with bevacizumab, although there was no
difference between females on the PC arm and PCB arm.
Females tended to have more grade 5 neutropenia or infec-
tions with neutropenia than males when treated with bevaci-
zumab and chemotherapy. However, no significant differ-
ences between the sexes in infection rates were found on the
PCB arm. Other general therapy toxicities such as nausea,
constipation, and anorexia were similar between the two
treatment arms. Females tended to experience more nausea
TABLE 5. Toxicity
Toxicity Types Sex
Treatment Arm
PC (n  440,
M  258, F  182)
PCB (n  427,
M  215, F  212)
3 4 5 pa 3 4 5 pa
Neutrophils M 17.4 27.0
F 15.9 24.1
Platelets M 1.4
F 0.5 1.9
Hypertension M 0.4 4.2
F 0.5 0.5 9.4 0.5 0.02
Anorexia M 3.5 0.4 3.3 0.5
F 3.8 6.1 0.5
Constipation M 3.5 0.4 1.4
F 2.7 4.2 0.5 0.08
Nausea M 4.3 4.7
F 7.7 7.5
CNS hemorrhage M 1.4 0.25
F
Hemoptysis M 0.5 0.9
F 0.5 0.5 0.5 1.4
Febrile neutropenia M 3.1 0.02 5.6
F 2.4 0.5
Infection with grade
3 or 4 neutropenia
M 1.6 0.8 1.9 0.5
F 1.6 0.9 0.5 0.9
Hyponatremia M 0.8 0.4 2.8 0.5
F 1.1 2.4 1.4
Abdominal pain M 1.6 0.9
F 0.5 0.5 5.2 0.01
Values are given as %.
a If not otherwise specified, p  0.05. p values are for comparing grade 3 or higher by sex within treatment arms.
CNS, central nervous system.
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than men across the treatment arms, although the difference
was not statistically significant. Females treated with PCB
had a higher rate of constipation, 4.7%, compared with males,
1.4% (p  0.05). Correspondingly, females also had a higher
rate of abdominal pain on the PCB arm compared with males
(5.2% versus 0.9%, respectively, p  0.01). There was no
statistically significant difference in the incidence of fatal
adverse events between males and females on the PCB arm
(1.9% and 5.2%, p  0.07) or between men and women on
the PC arm (0.4% and 0.5%).
Multivariable Analysis
The proportional hazards model adjusted for treatment,
sex, and a treatment by sex interaction term was fitted to test
whether the magnitude of treatment effects differed for fe-
males and males. The results for a treatment by sex interac-
tion were statistically significant (p  0.04). After adjusting
another model for baseline stratification factors, treatment,
sex, PS, stage, liver involvement, bone involvement, and
adrenal involvement, the following factors demonstrated sig-
nificantly worse survival: PC treatment (p  0.014), male
(p  0.0001), ECOG PS 1 (p  0.0001), recent diagnosis
versus recurrent (p  0.00015), liver involvement (p 
0.0015), bone involvement (p  0.0009), and adrenal in-
volvement (p  0.003). When a sex by treatment interaction
was added to this model thus adjusting for the above factors,
it was no longer significant (p  0.09). The estimated
treatment HR was 0.73 (CI, 0.58–0.90) for males and 0.97
(CI, 0.76–1.26) for females.
DISCUSSION
E4599 demonstrated an OS advantage in patients re-
ceiving PCB.8 In an unplanned, exploratory subset analysis,
females did not appear to have a survival benefit that males
did with PCB, although females on both arms survived longer
than males. In fact, the 13.1-month median survival of fe-
males in the PC arm was longer than in any previously
reported ECOG trial using a chemotherapy doublet in the
first-line treatment setting for NSCLC. Although retrospec-
tive analyses are limited and should be viewed with caution,
causes for the improved survival of females on the control
arm remain unclear. Presumably, differences in eligibility
criteria do not account for this difference, given that the
8.7-month median survival for males treated with PC on this
study is similar to the 8.3-month median survival observed on
E1594. Unmeasured differences in second-line therapy may
be responsible and may have the most effect on OS. How-
ever, the proportion of males and females on both the control
and experimental arms receiving second-line therapy were
roughly the same, although incomplete data collection limits
this analysis. It is possible that the surprisingly good survival
for females on the PC arm is due to chance alone or other
unmeasured prognostic factors such as epidermal growth
factor mutations, smoking status, or comorbidities, limiting
our ability to detect an improvement with the addition of
bevacizumab.
The poor prognostic characteristics of the males in the
PC arm and the females in the PCB arm do not fully explain
the differences in survival. Unfortunately, we do not have
epidermal growth factor mutation information on the subjects
in this study. Epidermal growth factor mutations are known
to be more common in neversmokers and are associated with
improved prognosis with any treatment.15 Females on PCB
may have been less likely to receive chemotherapy in the
second-line setting. However, complete data are not available
on second-line therapy prescribed. Females on PCB also expe-
rienced more toxicity and had more liver involvement compared
with females treated with PC alone. Adjusting for other factors,
the difference in the treatment effect between males and females
slightly narrowed but remained substantial.
To our knowledge, this is the first detailed report of a
sex difference in outcomes from bevacizumab. Reck et al.
reported subset differences by means of forest plots of HRs
on the AVAiL data (The phase III trial of cisplatin plus
gemcitabine with either placebo or bevacizumab as first-line
therapy for nonsquamous NSCLC). In both the 7.5 and 15
mg/kg bevacizumab dose groups, the OS was not statistically
improved for males or females, although the OS was greater
than 13 months for both groups. Specific data on sex differ-
ences and OS were not published. Interestingly, for PFS,
females had a statistically improved PFS at 15 mg/kg of
bevacizumab where males did not and vice versa at the 7.5
mg/kg bevacizumab dose. Data reported provided only min-
imal details regarding these differences. Unfortunately, be-
cause of this lack of information, the AVAiL trial does not
substantiate the findings of the ECOG 4599 sex differences
data.16,17 Other trials of bevacizumab in advanced colon
cancer demonstrated a benefit in both males and females.18
One possible reason for the differences observed in this
study may be related to sex hormones. Wakelee et al.19
examined ECOG 4599 and found an age-sex interaction in
that females younger than 60 years had an improved survival
when treated with PCB but females older than 60 did not.
Thus, menopausal status may play a role in these differences
as it has with paclitaxel poliglumex.20
Other factors that may cause differences in toxicity and
potentially a lack of benefit may include factors that affect
clearance of bevacizumab. Lu et al.21 described sex differ-
ences in the clearance and central compartment volume of
distribution (Vic). Clearance was 26% faster in males than in
females. Slower clearance in females could account for the
increased toxicity in females on the PCB arm. The postulated
reason why clearance is faster in males may be related to
greater muscle mass in males compared with females. In our
study, no measurements were available other than body mass
index to allow the examination of differences in muscle mass
between females on the two arms. The previous study found
an association between low serum albumin concentration
(29 g/L) and a 20% increase in clearance compared with an
average patient treated.21 Low serum albumin is a marker of
poor nutrition and poor liver function, which could be caused
by liver involvement with disease. However, liver involve-
ment with metastasis is probably not important for bevaci-
zumab because bevacizumab complexes are cleared by the Fc
receptor within the endothelial system and not the hepatocyte
or biliary system.22 Thus, an increased proportion of females
with liver involvement on the PCB arm would not explain
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higher toxicity rates. Also, in our study, the number of
subjects with low albumin levels was similar between the
sexes. However, the lower proportion of females with liver
metastases in the PC arm may have contributed to why that
group did better than expected.
Although both PFS and RR were improved with the
addition of bevacizumab in both males and females, our data
provide preliminary information that bevacizumab may have
different effects on OS in males and females with NSCLC.
The reasons for this remain unclear and need to be further
studied prospectively in future trials with this antibody.
Bevacizumab is an active drug in women with NSCLC,
where the addition of bevacizumab did result in significant
improvements in RR and PFS. The survival in the control
group of females treated with PC was unexpectedly high,
suggesting that the lack of a difference in survival may be
also in part related to characteristics of this group or due to
unknown differences in second-line therapy given in each
group. Because of these potential sex differences in treatment
benefits and a better OS in female patients with advanced
NSCLC, sex is an important stratification factor to include in
all randomized trials of advanced disease.
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